Table 2.
Summary of mutations in HIV-1 pro and RT for which significant correlations were found between the overall prevalence of community drug resistance (CDR) (i.e. non-weighted CDR) and transmitted drug resistance (TDR) measurements; p values were calculated with Spearman ranked correlation coefficient.
| Mutation | Rho (p-value) | Measurement Interval |
|---|---|---|
| D30N (pro) | 0.65 (0.031) | Yearly |
| 0.61 (0.005) | Every 6 months | |
| 0.57 (0.00l) | Every 4 months | |
| 0.43 (0.008) | Every 3 months | |
| M46I,L (pro) | 0.74 (0.008) | Yearly |
| 0.43 (0.066) | Every 6 months | |
| 0.44 (0.016) | Every 4 months | |
| 0.22 (0.199) | Every 3 months | |
| N88D,S (pro) | 0.68 (0.021) | Yearly |
| 0.58 (0.009) | Every 6 months | |
| 0.59 (<0.001) | Every 4 months | |
| 0.45 (0.006) | Every 3 months | |
| L74V,I (RT) | 0.46 (0.151) | Yearly |
| 0.35 (0.137) | Every 6 months | |
| 0.40 (0.032) | Every 4 months | |
| 0.24 (0.160) | Every 3 months | |
| V75M,T,A,S (RT) | 0.66 (0.027) | Yearly |
| 0.39 (0.101) | Every 6 months | |
| 0.18 (0.34) | Every 4 months | |
| 0.24 (0.157) | Every 3 months | |
| T215Y,F,I,S,C,D,V,E (RT) | 0.32 (0.336) | Yearly |
| 0.56 (0.012) | Every 6 months | |
| 0.30 (0.110) | Every 4 months | |
| 0.44 (0.006) | Every 3 months | |